Clinical Trial Update: Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 INNOVATE trial update examining safety, feasibility, and preliminary activity of combining TTFields therapy at 200 kHz with weekly paclitaxel in recur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• TTFields (Tumor Treating Fields) (Tumor Treating Fields)

Snippet

Sponsor: NovoCure Ltd. | Conditions: Ovarian Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN